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INTRODUCTION 
Lately, a new dimension has been added to the old operation of portacaval 
shunt by employing it to favorably alter the course of patients with several inborn 
errors of metabolism, Our own experience has been with glycogen storage dis-
ease, type II hyperlipoproteinemia, and Gaucher's disease. In addition, Folkman 
of the Boston Children's Hospital has recently performed portacaval shunt in a 
patient with alpha,-antitrypsin deficiency. We will discuss here these new uses 
for portal diversion, In addition, it will be interesting to look at possible 
mechanisms of the benefits of portacaval shunt, as these have been clarified by 
some recent advances in hepatic physiology. 
GLYCOGEN STORAGE DISEASE 
Trials of Portacaval Transposition 
The first portal diversion for hepatic glycogen storage disease was per-
formed almost 15 years ag023 in a girl who is still well today, By shortcircuiting 
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148 Putnam and Starzl 
splanchnic venous blood around the liver, it was hoped to make glucose more 
readily available to peripheral tissues and thus to relieve hypoglycemia, to coinci-
dentally deglycogenate the liver, and to palliate other metabolic derangements 
such as acidosis. In order to avoid the potential complication of hepatic en-
cephalopathy, which commonly follows portacaval shunt in dogs and other ani-
mals, the operation of portacaval transposition was selected, whereby the bypas-
sed portal flow is replaced with venous blood from the suprarenal inferior vena 
cava (Fig. 7-1). 
In this first patient the cavoportal anastomosis is still open more than a 
decade later with some flow to the liver (Fig. 7-2). However, most of the vena 
caval blood bypasses the liver through venous collaterals (Fig. 7-2). A second 
Fig. 7-1. The technique of portacaval transposition as it was carried out in the first 2 
patients with glycogen storage disease treated at our center by portal diversion. (From ref. 
23.) 
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Fig.7-2. Inferior vena cavagrams in March 1973 in Colorado Case 1 (Table 7-2). In this 
patient. in whom portacaval transposition (Fig. 7-1) had been performed 9~ years previ-
ously. there is a patent caval portal anastomosis (arrow). Significant flow through the 
liver. as well as around it by the azygous and other collaterals. was well seen at fluoros-
copy. (IYC. distal inferior vena cava; LRV. left renal vein; PY, portal vein.) (From ref. 
26.) 
transposition was soon performed by Riddell et al. 13 of Bristol. England, in a 
young boy who emigrated to Calgary, Canada, not long postoperatively. He was 
located and brought to Denver for follow-up studies. The portacaval anastomosis 
was open, but the vena caval to portal venous anastomosis had clotted (Fig. 7-3) 
so that the liver was not provided with replacement flow as was intended. 
Nevertheless, this patient is also well. 
Standardization of Operative and Supportive 
Care 
By the time 9 cases had been compiled throughout the world (Table 7-1), 
the basic operative procedure had become an end-to-side portacaval shunt. In our 
second patient submitted to portacaval transposition, the glycogen-laden liver 
was unable to transmit the vena caval flow and the child died within 2 days. In 
describing this easelS and in a simultaneous report by Hermann and Mercer' of 
the Cleveland Clinic, it was recommended that end-to-side portacaval shunt be 
used. In 1972 Folkman et al. 4 added the important observation that preoperative 
parenteral hyperalimentation could reduce the operative risk by normalizing the 
pre-existing hepatomegaly, acidosis. and other abnonnalities including hyper-
lipidemia. 
Seven of these first nine patients (Table 7-l) are still alive. Two of the seven 
surviving children had severe hypoglycemic brain injury before portal diversion. 
Despite marked metabolic improvement, Hermann's child died about 1'fl years 
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Fig. '·3 Studies of the Bristol case of portacaval transposition (Case 2 in Table 7·1). 
The original operation was on May 5, 1965, and the examination depicted was done in 
December 1971 and performed by Dr. R. J. Sommerville at the Foothills Hospital, 
Calgary, Alberta. (Left): Inferior vena cavagram showing obstruction at the anastomotic 
site (arrow). (IVC, distal inferior vena cava; LRV, left renal vein). (Right): Note the 
extensive collaterals via the azygous system and demonstration of a patent portacaval 
anastomosis (arrow) by means of retrograde catheterization. (lVC, proximal inferior vena 
cava; PV, portal vein). (From ref 26.) 
later. Sadly, Boley'sl young patient, who was still living 8 years later, was also 
brain damaged. As will be emphasized later, hypoglycemia may not be improved 
by portacaval shunt. Failure to appreciate this in some of the first cases may have 
been responsible for a potentially hannful relaxation of dietary measures after 
operation with further hypoglycemic brain damage. 
The Colorado Series 
Including our first 2 cases, we have now had experience with 9 patients 
(ages 3 to II years), of whom the last 7 have had simple portacaval 
shunL 16,23,2S,26 The enzyme defects were glucose-6-phosphatase (type I), 5 
cases; amylo-l-6-glucosidase (type III), 3 cases; and phosphorylase (type VI), 1 
case. Preoperatively, all the children (Table 7-2) had retardation of growth and 
all but the one with type VI disease had episodic hypoglycemia and acidosis. 
Effect on hypoglycemia. After portal diversion the preexisting hypo-
glycemia was not relieved in some children, e.g., the one whose glucose tolerance 
tests are shown in Figure 7-4 before and after operation. This child continued to 
require night feedings. The hypoglycemia was variably improved in the other 
patients. 
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Table 7-2 
Children with Glycogen Storage Disease Treated at the University 
of Colorado by Portal Diversion 
Case No. 
(Date) 
1* 
(1963) 
2* 
(1968) 
3 
( 1972) 
4 
( 1972) 
5 
(1972) 
6 
(1972) 
7 
(1972) 
8 
(1973) 
9 
(1973) 
Symptoms 
Age at 
Operation (Years) Type Hypoglycemia Acidosis Growth Retardation 
8Y.! III x x x 
7 I x x x 
7 x x x 
11 x x x 
10 IV x 
5 III x x x 
3 III x x x 
8 x x x 
13 x x x 
*~ese 2 patients had portacaval transposition. All others had end·to·side portacaval shunt. 
One reason for the continuing hypoglycemia may be the major increases in 
peripheral insulin after shunting. It has been known from the work of Lockwood 
et al. 11 that the peripheral insulin curves in patients with glycogen storage disease 
are flat (see preoperative study in Fig. 7-4). After shunting, the insulin response 
curves to glucose stimulation, months to years postoperatively, have been normal 
or distinctly supra-normal in several of our cases in whom these parameters were 
measured (Fig. 7-4). In tum, the flooding of insulin to the periphery may well 
have been the main reason for the growth spurt which we will describe later. In 
any event, it would be a mistake, at least in some of the cases, to try to com· 
pletely eliminate dietary hypoglycemia management. 
Effect on the liver. Liver glycogen concentrations were little changed 
from the preoperative levels, from 5 months to more than 9 years after portal 
diversion.26 Even so, the liver in several of the children underwent obvious 
shrinkage (Fig. 7·S), which could be confirmed by planimetry. Even if such 
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Fig. 7·4. Preoperative and postoperative oral glucose tolerance 
tests in a child with type I glycogen storage disease. Note the 
tremendous increase in peripheral venous insulin concentrations 
after portal diversion. 
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obvious shrinkage did not occur, postoperative biopsies always showed a diminu-
tion in hepatocyte size. %6 Any changes in liver size were. of course, magnified by 
virtue of the accelerated body growth which resulted in the body growing up 
around the liver. 
Other metabolic abnormalities. In contrast to the incomplete relief of 
hypoglycemia. all components of the hyperlipidemia which is characteristic of 
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Fig. 7-5. AP 99m technetium liver scans in a child with type VI (phosphorylase de-
ficiency) disease (Case 5 in Table 7-2). The cm2 areas were obtained by planimetry from 
the anteroposterior projectiuns. (From ref. 26.) 
type I disease were profoundly and permanently relieved. This was first observed 
by Hermann and Mercer' and confirmed by Folkman et al. 4 and in our own 
cases.1I Correction of other metabolic defects, including abnormal bleeding, uric 
acid elevations, and abnormal calcium metabolism, was also observed. 26 
Effect on growth. Another major effect was on body growth. In our origi-
nal case, a remarkable growth spurt was noted.23 Accelerated height increases 
have been seen in all of our patients followed for sufficient time intervals. 25 
During the first year after operation, these previously dwarfed children have 
grown at the rate of between 0.5 and 1 em every month. 
Comparison of x-rays of the wrist and hands before and 1 Ph months after 
operation shows the phenomenal effect of bone age doubling in a child with type 
I disease (Fig. 7-6). In addition to growth, mineralization has occurred and new 
bones have appeared in the wrists. Circulating somatotropin in these patients was 
normal. As mentioned earlier, the growth spurts may have been at least partially 
attributable to the increased insulin distribution to the periphery, since insulin has 
recent1y been recognized to be a major growth hormone comparable in potency to 
somatotropin. 14 
Alternative Therapy 
The observations of Folkman et aJ.4 about the corrective effects of preopera-
tive hyperalimentation were aJluded to earlier. Because of the obvious limitations 
of chronic intravenous infusion therapy, this kind of treatment is not practical 
clinically. Burr and his coworkers2 have reported marked relief of biochemical 
abnormalities, platelet dysfunction, and hepatomegaly in a 16-year-old boy with 
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Fig. 7-6. The dramatic wrist and hand bone growth in Colorado Case 3 (Table 7-2) in 
the first t l'fz postoperative months. The bracket on the left index finger is 5 cm in length. 
In addition to the size change, note the mineralization that has occurred, as well as the 
appearance of new bones in the wrist. (From ref. 26.) 
type I disease, who was treated for 23 days with continuous intragastric infusion 
of carbohydrate and protein . 
Folkman and his associates (persorUJl communication, 1975), in another 
ingenious innovation, are trying the continuous intragastric infusion of a sugar 
solution which is delivered through a gastrostomy by a finely calibrated, 
battery-operated pump. With prolonged intragastric hyperalimentation, many of 
the metabolic effects seen with parenteral hyperaIimentation and after portal 
diversion have been duplicated, including accelerated body growth. 
HYPERLIPIDEMIA 
In the glycogen storage diseases which we have been discussing, the livers 
are always patently abnormal because of the accumulation of glycogen, and often 
because of fibrosis.26 By contrast, the liver is morphologically normal in 
homozygous type I1 hyperlipoproteinemia, a second metabolic disease for which 
portacaval shunt has been performed. The explanation for the elevated serum 
cholesterol and low density lipoproteins (LDL) in this autosomal-dominant inher-
ited disorder is by no means understood. Goldstein and Brown 1 have s~ggested 
that there may be an absence of or a defect in the cell surface receptor sites which 
normally bind and transport LDL cholesterol into the cell. Because cholesterol 
does not enter the cell adequately, there is an absence of normal feedback 
suppression of cholesterol synthesis. 
Whatever its cause, the homozygous form of type I1 hyperlipoproteinemia 
has a shockingly poor prognosis even with attempts at rigorous medical therapy. ~ 
Lipid-rich deposits are laid down in widely separated superficial and deep parts 
of the body. Lipid accumulations in the vascular system cause aortic valvular 
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stenosis and coronary artery disease. Such cardiovascular complications are clas-
sically responsible for the precocious deaths from this disorder. 
Colorado Cases 
A young girl with homozygous type n hyperlipidemia was followed and 
treated medically at the university clinics for most of her life. By the time she 
was 7 years old, she had demonstrable aortic stenosis (Table 7-3) and significant 
angina pectoris. Portal diversion was first seriously considered for this patient in 
the spring of 1972 when she was 10 years of age. Unfortunately, a negative 
decision was made. In November 1972 her cardiac symptoms had become disabl-
ing. At that time she was given a course of parenteral hyperalimentationl9 similar 
to that introduced by Folkman et al. 4 for the preparation of patients with type I 
glycogen storage disease for portal diversion. A delayed but definite lowering of 
the previously refractory hypercholesterolemia was seen (Fig. 7-7), which out-
lasted the intravenous therapy by several weeks. 19 Parenthetically, the an-
tilipidemic effect of parenteral hyperalimentation in such patients has been 
confirmed in two recent papers, one by Torsvik et a1. 28 from the United States 
and the other by Stein et al.27 from South Africa. 
In January 1973 the patient suffered a massive myocardial infarction. About 
2 months after the infarction, end-to-side portacaval shunt was performed. Post-
operatively, there was a dramatic fall in serum cholesterol concentration from 
about 800 mg/loo ml to nearly normal (Fig. 7-8). The cutaneous and tendinous 
lesions melted away (Fig. 7-9). By cardiac catheterization (Table 7-3), the gra-
dient caused by severe aortic stenosis regressed. There also seemed to be reversal 
of atherosclerosis on coronary arteriography. However, three areas of residual 
stenosis remained. The most severe stenosis is shown in Figure 7-10. 
Her course was one of steady improvement. 17 .19 However, on September 
23, 1974, while coming home from school, she collapsed in the street and died. 
The conclusion from her autopsy18 was that death was caused by a cardiac 
arrhythmia. The old ventricular aneurysm was found but no new infarction was 
identified. The residual high-grade coronary artery stenoses were identified. The 
portacaval shunt was patent. The liver was grossly normal, but the hepatocytes 
were smaller than before operation. The liver cells contained some abnormalities 
Table 7-3 
Findings of Aortic Stenosis in a Child with Homozygous Type Il 
Hyperlipidemia 
Age 7 
Age II 
16 Months after portacaval shunt 
Aortic Systolic Murmur 
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Fig. 7-7. Changes in cholesterol and triglycerides during intravenous hyperalimentation 
in a 12·year-old girl with homozygous type II hyperlipoproteinemia. (From ref. 19.) 
of the organelles as had been reported from an earlier biopsy .19 Survival from the 
time of portacaval anastomosis had been almost 19 months. 
We have also performed a portacaval shunt on a 7-year-old girl who had 
serum cholesterol values averaging 1000 mg/ 100 ml preoperatively. Nine months 
later the cholesterol was about 500 mg/l00 rnl (Fig. 7-11). Hepatic lipoprotein 
synthesis in this patient, as measured by Brown and Goldstein of Dallas (per-
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Fig. 7-8. Cholesterol concentrations before and during the first 6 months after portal 
diversion. The preoperative value represents the mean of nine determinations::!: I SO. 
The operation was performed on March I, 1973. (From ref. \9.) 
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Fig. '·9. Patient's hands (A) 2 weeks before and (B) 16 months after portacaval shunt 
for type n hyperlipidemia. 
sonal communication) has been sharply reduced. Our own canine and baboon 
studies have also indicated that portal diversion greatly reduces hepatic lipid 
synthesis. 21 
Other Cases Elsewhere 
We have information on 8 other patients, 6 from South Africa, submitted to 
portacaval shunt for homozygous type n hyperlipidemia. All these patients had a 
significant cholesterol reduction except a girl from Cape Town. In her case the 
shunt was proved to have clotted. Even more interesting, a huge collateral 
coming from the general area of the pancreas had revascularized the tied off 
central portal vein, thus explaining the therapeutic failure in this case (Cywes, 
personal communication, 1974). 
Four South African patients studied in the Lipid Disorders Centre of the 
University of Witwatersrand, Johannesburg, were recently reported by Stein et 
a1. 27 This article was of singular importance since it presented data from multiple 
patients, confirming several potentially important observations made in our first 
case. These included the antilipidemic effect of parenteral hyperalimentation, the 
sustained lipid-lowering effect of portal diversion, the melting away of visible 
xanthomatous deposits, and the relief of angina pectoris and other cardiovascular 
symptoms. There seems reason to hope that the lethal lesions characteristic of 
I 
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Fig. '·10. Coronary arteriogram 16 months after portacaval shunt. The diffuse narrow· 
ing of the coronary arteries seen in the preoperative study had resolved except for three 
discrete areas of occulsive disease, one of which is displayed here (arrow). (From ref. 
25.) . 
homozygous type II hyperlipoproteinemia may undergo reversal after portal di-
version. 
JUVENILE GAUCHER'S DISEASE AND OTHER 
POSSIBILITIES 
The third inborn error of metabolism which we have treated with portacaval 
shunt is Gaucher's disease or the glucosyl ceramide lipidosis. A 14-year-old-boy, 
in whom this disorder had led to hepatic failure, uremia, and intractable ascites, 
was referred to us to be considered for liver transplantation. Instead, a portacaval 
shunt was performed with amelioration of all these symptoms. 
It is interesting that ImparatolO of New York reported a similar case in 1960 
with the same gratifying result. In a recent correspondence (personal communi-
cation, 1975), he has given us an IS-year follow-up of his patient, who is still 
alive. Unfortunately, this man, who is now 28 years old, suffers from a convul-
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Fig. 7-11. Serum cholesterol values during the first 6 months 
after portacaval shunt in a 7-year-old girl with homozygous type IT 
hyperlipidemia. The preoperative value represents the mean (:!: 
ISD) of 12 determinations. 
sive disorder of such severity that he is institutionalized. The seizures reflect the 
natural history of juvenile Gaucher's disease.6 
In a discussion of our presentation at the American Pediatric Surgical As-
sociation in Puerto Rico on April 12, 1975, Folkman (personal communication) 
reported a gratifying result after portal diversion in an infant with rapidly prog-
ressive alphal-antitrypsin deficiency. Somewhat surprisingly, his patient has had 
the same kind of growth spurt as seen after portacaval shunt for glycogen storage 
disease . 
In both Gaucher's disease and alpha I-antitrypsin deficiency, it is possible to 
envision an improvement in health after portacaval shunt for hemodynamic 
reasons and without the kind of specific metabolic amelioration that has been 
seen after this procedure in glycogen storage disease and hyperlipidemia. On the 
other hand, a metabolic component to the therapeutic benefit has not by any 
means been ruled out. 
MECHANISMS OF BENEFIT 
It was pointed out earlier that increased peripheral insulin concentrations 
after portacaval shunt may explain the accelerated growth of the children with 
glycogen storage disease. 
What is the explanation for the other metabolic effects of portal diversion in 
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this disorder and in idiopathic hyperlipidemia? Publications from our laboratory 
beginning 10 years ago1%'22 and recently summanzed15 ,20,24 have shown that 
venous blood returning from the splanchnic organs has special liver-sustaining 
qualities that are not provided by equal volumes of other venous or arterial blood. 
These so-called hepatotrophic effects on hepatocytes include the support of 
hypertrophy, hyperplasia, glycogen storage, and various metabolic functions. On 
the basis of biochemical evidence,2o we have ascribed these actions mainly to the 
endogenous hormones, especially insulin, that are released by the splanchnic 
viscera and thus arrive at the liver in high physiologic concentrations. Recently, 
we have shown in several experimental models in dogs that such effects are 
partly eliminated by the creation of alloxan diabetes or after total pancreatec-
tomy, emphasizing again the primal hepatotrophic role of insulin. 24 
We have also published evidence that these hormonal substances in portal 
venous blood which profoundly affect hepatic structure, function, and the capac-
ity for regeneration are the same as those which subserve hepatic lipid synth-
esis.:u Such hormone effects on the liver probably assume amplified importance 
in hepatic homeostasis because the richness of nutrients in the same portal blood 
presumably contributes to significant hormone-substrate interrelations. 
With end-to-side portacaval shunt, both nutritional and hormonal substances 
are diverted extrahepatically, and this may contribute to the desired postoperative 
effects (Fig. 7-12) in glycogen storage disease as well as in hyperlipidemia. As 
mentioned earlier, hepatic cholesterol synthesis is very significantly, and appa-
rently permantly, depressed after portal diversion.21 This explains, at least in 
part, the lipid lowering influence of this operation. 
These clinical applications accept a trade-off of distinctly suboptimal condi-
tions of liver perfusion in return for metabolic improvements that are derivative 
from the suboptimal conditions. Realization of this fact, and the potential con-
sequent hazards, will encourage a conservative and discriminating attitude about 
the recommendation of portacaval shunt for patients with glycogen storage or 
Gaucher's disease. 
As to hyperlipidemia, we believe that portacaval shunt should be restricted 
at the present time to the highly lethal homozygous type II variety and then only 
if medical management fails. The certain establishment of the diagnosis and the 
appropriate investigation of each case require that such patients be seen in institu-
tions that have a sophisticated interest in lipid metabolism. It is hoped that the 
proper study of these cases will lead to information that can be applied to other 
forms of hyperlipidemia and the resulting premature atherosclerosis. 
THE SPECTER OF ENCEPHALOPATHY 
The main reason to maintain a conservative attitude about portal diversion is 
the syndrome of hepatic encephalopathy, which is caused by this procedure in 
animals, even though they have normal livers at the time of operation. A popular 
'II 
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• GLYCOGENATION 
• DEGLYCOGENATION 
Fig. 7-12. Summary of experimental results of canine experiments20 in which one 
portion of the liver received portal venous inflow from the pancreas and the other portion 
received inflow from the intestine. The "food-dominated" hepatic fragment underwent 
atrophy and deglycogenation, whereas the "hormone-dominated" fragment had hyper-
trophy, hyperplasia, and glycogen storage. These experiments which permitted dissoica-
tion of nutritional and hormonal influences indicated that the latter were more influential 
than the former in affecting liver structure and function. (From ref. 26.) 
misconception is that the complication of encephalopathy is species specific to 
the dog. in which it is sometimes called "meat intoxication." 
However, in a recent article,S evidence was summarized and annotated 
showing that encephalopathy can be produced in widely divergent animal species 
including rodents, swine, and subhuman primates. We have studied eight ba-
boons after complete portal diversion. Five of the animals developed typical 
hepatic encephalopathy within Ph to 5 months. In addition to the neurologic 
manifestations, the baboons had profound weight loss, muscle wasting, and 
alopecia. 
If there is a species peculiarity pertaining to portal diversion, the specificity 
would seem to be the resistance of humans to encephalopathy and other compli-
cations of the procedure. Although this has been well documented by the experi-
ence with glycogen storage disease and idiopathic hyperlipidemia, it cannot be 
forgotten that ruinous complications many years later are still a possibility, 
however remote. 
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SUMMARY 
Portal venous diversion, which has been employed for many years for the 
purely hemodynamic objectives of stopping hemmorrhage from esophageal var-
ices or less commonly to treat intractable ascites, has now been used for specific 
metabolic purposes in treating three inborn errors of metabolism-glycogen stor-
age disease, hyperlipidemia, and Gaucher's disease. 
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